About: Extended effect of short-course azithromycin for the treatment of diarrhoea in children on antimicrobial resistance in nasopharyngeal and intestinal bacteria: Study Protocol for the antimicrobial resistance sub-study of the multicountry AntiBiotics for Children with Diarrhea (ABCD) trial.

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Extended effect of short-course azithromycin for the treatment of diarrhoea in children on antimicrobial resistance in nasopharyngeal and intestinal bacteria: Study Protocol for the antimicrobial resistance sub-study of the multicountry AntiBiotics for Children with Diarrhea (ABCD) trial. Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Extended effect of short-course azithromycin for the treatment of diarrhoea in children on antimicrobial resistance in nasopharyngeal and intestinal bacteria: Study Protocol for the antimicrobial resistance sub-study of the multicountry AntiBiotics for Children with Diarrhea (ABCD) trial.
Source	MedRxiv
abstract	Antimicrobial resistance (AMR) is a major public health challenge worldwide, threatening the important gains that have been made in reducing mortality due to infectious diseases. Despite current World Health Organization guidelines restricting antibiotics to a small subset of children with dysentery or suspected cholera, many children with diarrhea continue to be treated with antibiotics. We aim to determine the impact of a 3-day course of azithromycin on the risk of AMR at 90 and 180 days after treatment, among a subset of children and their household contacts enrolled into a multi-country, randomized, double-blind, placebo-controlled clinical trial of azithromycin children under 2 years with diarrhea in low income settings, Methods and analysis The AntiBiotics for Children with Diarrhea (ABCD) trial is testing the efficacy of a 3-day course of azithromycin, compared to placebo, in reducing mortality and linear growth faltering in the subsequent 6 months among 11,500 children aged 2-23 months of age across multiple sites in Bangladesh, India, Kenya Malawi, Mali, Pakistan and Tanzania with diarrhea and one or more of the following; dehydration, severe stunting, or moderate wasting (https://clinicaltrials.gov/ct2/show/NCT03130114). A sub-set of enrolled children are randomly selected to participate in a sub-study of AMR. A fecal sample (stool or rectal swab) will be collected at baseline from all enrolled children. A fecal sample and a nasopharyngeal (NP) swab will be collected at day 90 and 180 after enrolment from participating children and a close household child contact. Escherichia coli and Streptococcus pneumoniae will be isolated and Minimum Inhibitory Concentration for azithromycin and other commonly used antibiotics will be determined and compared between trial arms. Ethics and dissemination This study was reviewed by an independent ethical review committee. Dissemination of results is planned to local and international policy makers and the public.
has issue date	2020-07-19(xsd:dateTime)
bibo:doi	10.1101/2020.07.17.20156224
has license	medrxiv
sha1sum (hex)	f4b4b65cad8c16be9a22f314246f5d449322d8ec
schema:url	https://doi.org/10.1101/2020.07.17.20156224
resource representing a document's title	Extended effect of short-course azithromycin for the treatment of diarrhoea in children on antimicrobial resistance in nasopharyngeal and intestinal bacteria: Study Protocol for the antimicrobial resistance sub-study of the multicountry AntiBiotics for Children with Diarrhea (ABCD) trial.
resource representing a document's body	covid:f4b4b65cad8c16be9a22f314246f5d449322d8ec#body_text
is schema:about of	named entity 'risk' named entity 'dysentery' named entity 'Protocol' named entity 'MULTI' named entity 'DIARRHEA' named entity 'Extended' named entity 'diarrhoea' named entity 'Children' named entity 'azithromycin' named entity 'cholera' named entity 'World Health Organization' named entity 'infectious diseases' named entity 'public health' named entity 'Antimicrobial resistance' named entity 'double-blind, placebo-controlled' named entity 'AntiBiotics' named entity 'azithromycin' named entity 'antimicrobial resistance' named entity 'antimicrobial resistance' named entity 'intestinal bacteria' named entity 'Asian' named entity 'E. coli' named entity 'parasitic' named entity 'infectious disease' named entity 'preprint' named entity 'World Health Organization' named entity 'pneumococcal' named entity 'Escherichia coli' named entity 'antibiotics' named entity 'medRxiv' named entity 'inoculation' named entity 'serum' named entity 'glycerol' named entity 'preprint' named entity 'CC-BY-NC-ND 4.0' named entity 'preprint' named entity 'diarrhoea' named entity 'Bangladesh' named entity 'E. coli' named entity 'sub-Saharan Africa' named entity 'Gram-negative' named entity 'Beckman Coulter' named entity 'bile' named entity 'preprint' named entity 'S. pneumoniae' named entity 'preprint' named entity 'antibiotic resistance' named entity 'India' named entity 'informal vendors' named entity 'mass drug administration' named entity 'inoculum' named entity 'inoculation' named entity 'azithromycin' named entity 'antimicrobials' named entity 'sensitivity testing' named entity 'diarrhea' named entity 'placebo group' named entity 'health care' named entity 'yeast extract' named entity 'epidemiologic' named entity 'Co2' named entity 'medRxiv' named entity 'preprint' named entity 'commensal organisms' named entity 'Africa' named entity 'self-limiting' named entity 'TSA' named entity 'trial testing' named entity 'Minimum inhibitory concentration' named entity 'randomly selected' named entity 'Asian' named entity 'CLSI' named entity 'meningitis' named entity 'antibiotics' named entity 'S. pneumoniae' named entity 'Tryptone' named entity 'S. pneumoniae' named entity 'Objective 1' named entity 'microliters' named entity 'diarrhea' named entity 'turbidity' named entity 'placebo' named entity 'sheep' named entity 'preprint' named entity 'preprint' named entity 'turbidity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software